 Aravindhan Veerapandiyan
Concepts (224)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscular Dystrophy, Duchenne | 9 | 2025 | 25 | 4.220 |
Why?
| | Muscular Atrophy, Spinal | 5 | 2024 | 14 | 2.920 |
Why?
| | Oligonucleotides | 4 | 2020 | 76 | 2.000 |
Why?
| | Genetic Therapy | 6 | 2024 | 124 | 1.790 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 178 | 1.580 |
Why?
| | Coronavirus Infections | 3 | 2020 | 189 | 1.560 |
Why?
| | Spastic Paraplegia, Hereditary | 2 | 2022 | 2 | 1.530 |
Why?
| | Mutation | 12 | 2023 | 1339 | 1.450 |
Why?
| | Disease Management | 2 | 2020 | 186 | 1.190 |
Why?
| | Dystonic Disorders | 2 | 2023 | 7 | 1.160 |
Why?
| | Pandemics | 4 | 2022 | 586 | 1.090 |
Why?
| | Child | 25 | 2025 | 7188 | 1.020 |
Why?
| | Humans | 51 | 2025 | 52469 | 0.980 |
Why?
| | Morpholinos | 1 | 2025 | 1 | 0.960 |
Why?
| | Spasms, Infantile | 2 | 2018 | 30 | 0.920 |
Why?
| | Epilepsy | 2 | 2022 | 187 | 0.900 |
Why?
| | Neuromuscular Diseases | 1 | 2024 | 31 | 0.850 |
Why?
| | Spinal Muscular Atrophies of Childhood | 2 | 2020 | 9 | 0.840 |
Why?
| | Recombinant Fusion Proteins | 2 | 2024 | 175 | 0.830 |
Why?
| | Peroneal Neuropathies | 2 | 2021 | 5 | 0.830 |
Why?
| | Intellectual Disability | 2 | 2022 | 128 | 0.830 |
Why?
| | Dystonia | 1 | 2023 | 11 | 0.810 |
Why?
| | Adolescent | 18 | 2025 | 6708 | 0.790 |
Why?
| | Nerve Tissue Proteins | 2 | 2021 | 192 | 0.750 |
Why?
| | Male | 31 | 2025 | 26794 | 0.740 |
Why?
| | Myasthenic Syndromes, Congenital | 1 | 2021 | 8 | 0.730 |
Why?
| | Child, Preschool | 14 | 2025 | 4034 | 0.710 |
Why?
| | Chromosomes, Human, Pair 22 | 2 | 2011 | 38 | 0.700 |
Why?
| | Fasciculation | 1 | 2020 | 2 | 0.680 |
Why?
| | Isaacs Syndrome | 1 | 2020 | 2 | 0.680 |
Why?
| | Hereditary Sensory and Motor Neuropathy | 1 | 2020 | 3 | 0.680 |
Why?
| | Seizures | 3 | 2018 | 209 | 0.670 |
Why?
| | Muscular Dystrophies | 1 | 2020 | 14 | 0.670 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2020 | 10 | 0.670 |
Why?
| | Codon, Nonsense | 1 | 2020 | 28 | 0.660 |
Why?
| | Consensus | 2 | 2024 | 191 | 0.660 |
Why?
| | Anticonvulsants | 2 | 2012 | 134 | 0.650 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2020 | 86 | 0.650 |
Why?
| | Charcot-Marie-Tooth Disease | 1 | 2019 | 7 | 0.640 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 3 | 2024 | 179 | 0.640 |
Why?
| | Glucocorticoids | 3 | 2020 | 238 | 0.640 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2020 | 33 | 0.640 |
Why?
| | Phenotype | 3 | 2020 | 799 | 0.630 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 200 | 0.620 |
Why?
| | Encephalitis | 2 | 2017 | 39 | 0.620 |
Why?
| | Infant | 9 | 2020 | 3691 | 0.600 |
Why?
| | Multiple Sclerosis | 1 | 2019 | 72 | 0.590 |
Why?
| | Chromosome Duplication | 1 | 2018 | 7 | 0.590 |
Why?
| | Survival of Motor Neuron 1 Protein | 1 | 2018 | 3 | 0.590 |
Why?
| | Munc18 Proteins | 1 | 2018 | 3 | 0.580 |
Why?
| | Electroencephalography | 6 | 2018 | 303 | 0.580 |
Why?
| | Spinal Puncture | 1 | 2018 | 17 | 0.580 |
Why?
| | Microfilament Proteins | 1 | 2018 | 44 | 0.580 |
Why?
| | Dystrophin | 3 | 2024 | 6 | 0.570 |
Why?
| | Epilepsies, Myoclonic | 1 | 2018 | 14 | 0.570 |
Why?
| | Head | 1 | 2018 | 71 | 0.560 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2018 | 96 | 0.560 |
Why?
| | Chromosome Deletion | 3 | 2018 | 140 | 0.540 |
Why?
| | Delivery of Health Care | 1 | 2020 | 323 | 0.540 |
Why?
| | DiGeorge Syndrome | 3 | 2012 | 19 | 0.530 |
Why?
| | Central Nervous System Diseases | 1 | 2017 | 27 | 0.530 |
Why?
| | Pedigree | 3 | 2022 | 125 | 0.530 |
Why?
| | Carrier Proteins | 1 | 2018 | 318 | 0.500 |
Why?
| | Muscular Diseases | 2 | 2020 | 63 | 0.490 |
Why?
| | Female | 21 | 2024 | 28192 | 0.450 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 524 | 0.430 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 1162 | 0.390 |
Why?
| | Brain | 2 | 2018 | 1321 | 0.390 |
Why?
| | Epilepsy, Complex Partial | 1 | 2012 | 3 | 0.380 |
Why?
| | Carbamazepine | 1 | 2012 | 13 | 0.380 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 2011 | 3 | 0.350 |
Why?
| | Pyridoxal Phosphate | 1 | 2011 | 6 | 0.350 |
Why?
| | Cephalometry | 1 | 2011 | 18 | 0.350 |
Why?
| | Myoglobinuria | 1 | 2010 | 2 | 0.350 |
Why?
| | Triazines | 1 | 2011 | 25 | 0.350 |
Why?
| | Epilepsy, Absence | 1 | 2011 | 11 | 0.350 |
Why?
| | Ocular Motility Disorders | 1 | 2011 | 17 | 0.350 |
Why?
| | Velopharyngeal Insufficiency | 1 | 2011 | 18 | 0.340 |
Why?
| | BRCA2 Protein | 1 | 2010 | 19 | 0.340 |
Why?
| | Pseudolymphoma | 1 | 2010 | 4 | 0.340 |
Why?
| | Prednisolone | 3 | 2020 | 56 | 0.330 |
Why?
| | Retrospective Studies | 7 | 2021 | 6643 | 0.330 |
Why?
| | Mutation, Missense | 1 | 2010 | 108 | 0.330 |
Why?
| | Treatment Outcome | 5 | 2024 | 5471 | 0.320 |
Why?
| | Drug Overdose | 1 | 2011 | 164 | 0.300 |
Why?
| | Diagnosis, Differential | 3 | 2020 | 1044 | 0.280 |
Why?
| | Myocarditis | 2 | 2024 | 48 | 0.270 |
Why?
| | Young Adult | 7 | 2024 | 4326 | 0.250 |
Why?
| | Insurance Claim Review | 1 | 2025 | 40 | 0.240 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 399 | 0.230 |
Why?
| | Follow-Up Studies | 3 | 2021 | 2288 | 0.230 |
Why?
| | Muscle, Skeletal | 1 | 2010 | 809 | 0.230 |
Why?
| | Gene Transfer Techniques | 1 | 2024 | 44 | 0.230 |
Why?
| | Heterozygote | 2 | 2023 | 91 | 0.230 |
Why?
| | United States | 3 | 2025 | 5225 | 0.220 |
Why?
| | Dependovirus | 1 | 2024 | 103 | 0.210 |
Why?
| | Mental Disorders | 2 | 2024 | 428 | 0.200 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2023 | 56 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 3 | 2018 | 1536 | 0.190 |
Why?
| | Adenosine Triphosphatases | 1 | 2022 | 91 | 0.190 |
Why?
| | Semaphorins | 1 | 2021 | 5 | 0.180 |
Why?
| | Adult | 8 | 2024 | 14151 | 0.180 |
Why?
| | Atrophy | 1 | 2022 | 49 | 0.180 |
Why?
| | Patient Care Planning | 1 | 2022 | 68 | 0.180 |
Why?
| | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2021 | 4 | 0.180 |
Why?
| | Cell Adhesion Molecules | 1 | 2021 | 88 | 0.180 |
Why?
| | Receptors, Cell Surface | 1 | 2021 | 111 | 0.170 |
Why?
| | Cohort Studies | 2 | 2018 | 1550 | 0.170 |
Why?
| | Introns | 2 | 2018 | 54 | 0.170 |
Why?
| | Muscle Cramp | 1 | 2020 | 5 | 0.170 |
Why?
| | Recovery of Function | 1 | 2021 | 201 | 0.160 |
Why?
| | Flavoproteins | 1 | 2019 | 5 | 0.160 |
Why?
| | Injections, Spinal | 1 | 2019 | 21 | 0.160 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2019 | 23 | 0.160 |
Why?
| | Health Services Accessibility | 1 | 2024 | 438 | 0.160 |
Why?
| | Hand Strength | 1 | 2019 | 23 | 0.160 |
Why?
| | Palliative Care | 1 | 2022 | 213 | 0.160 |
Why?
| | Physical Endurance | 1 | 2019 | 34 | 0.160 |
Why?
| | Facial Paralysis | 1 | 2020 | 25 | 0.160 |
Why?
| | Muscle Weakness | 1 | 2020 | 45 | 0.160 |
Why?
| | Neurologic Examination | 1 | 2019 | 73 | 0.160 |
Why?
| | Membrane Proteins | 1 | 2022 | 336 | 0.160 |
Why?
| | Age of Onset | 1 | 2019 | 110 | 0.160 |
Why?
| | Steroids | 1 | 2019 | 60 | 0.160 |
Why?
| | Abnormalities, Multiple | 2 | 2011 | 168 | 0.160 |
Why?
| | Age Factors | 3 | 2018 | 1131 | 0.150 |
Why?
| | Scoliosis | 1 | 2019 | 62 | 0.150 |
Why?
| | Spinal Fusion | 1 | 2019 | 71 | 0.150 |
Why?
| | Aminomethyltransferase | 1 | 2018 | 1 | 0.150 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2018 | 5 | 0.150 |
Why?
| | Hyperammonemia | 1 | 2018 | 24 | 0.150 |
Why?
| | Activities of Daily Living | 1 | 2019 | 183 | 0.150 |
Why?
| | Lumbosacral Region | 1 | 2018 | 13 | 0.150 |
Why?
| | X-Rays | 1 | 2018 | 55 | 0.150 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 166 | 0.140 |
Why?
| | Neuraminidase | 1 | 2018 | 4 | 0.140 |
Why?
| | Mucolipidoses | 1 | 2018 | 4 | 0.140 |
Why?
| | Pons | 1 | 2017 | 33 | 0.140 |
Why?
| | Methylprednisolone | 1 | 2017 | 41 | 0.140 |
Why?
| | Brain Stem | 1 | 2017 | 57 | 0.130 |
Why?
| | Prevalence | 1 | 2020 | 1016 | 0.130 |
Why?
| | Disease Progression | 1 | 2019 | 872 | 0.130 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 1680 | 0.130 |
Why?
| | Quality of Life | 1 | 2022 | 881 | 0.120 |
Why?
| | Middle Aged | 4 | 2024 | 13084 | 0.120 |
Why?
| | T-Lymphocytes | 1 | 2017 | 327 | 0.110 |
Why?
| | Chronic Disease | 1 | 2017 | 588 | 0.110 |
Why?
| | RNA, Messenger | 1 | 2018 | 1139 | 0.110 |
Why?
| | Aged | 3 | 2021 | 10193 | 0.110 |
Why?
| | Antibodies | 2 | 2012 | 150 | 0.110 |
Why?
| | Kv1.1 Potassium Channel | 1 | 2013 | 2 | 0.110 |
Why?
| | Dipeptides | 1 | 2012 | 21 | 0.100 |
Why?
| | Caregivers | 2 | 2024 | 238 | 0.100 |
Why?
| | Aspartic Acid | 1 | 2012 | 45 | 0.090 |
Why?
| | Folic Acid Deficiency | 1 | 2012 | 43 | 0.090 |
Why?
| | Folate Receptor 1 | 1 | 2012 | 27 | 0.090 |
Why?
| | Prefrontal Cortex | 1 | 2012 | 84 | 0.090 |
Why?
| | Ear | 1 | 2011 | 15 | 0.090 |
Why?
| | Hypoparathyroidism | 1 | 2011 | 5 | 0.090 |
Why?
| | Immune System Diseases | 1 | 2011 | 8 | 0.090 |
Why?
| | Facies | 1 | 2011 | 36 | 0.090 |
Why?
| | Eye Abnormalities | 1 | 2011 | 24 | 0.090 |
Why?
| | Nose | 1 | 2011 | 33 | 0.090 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2011 | 78 | 0.090 |
Why?
| | Epilepsies, Partial | 1 | 2011 | 14 | 0.090 |
Why?
| | Platybasia | 1 | 2011 | 5 | 0.090 |
Why?
| | Frontal Lobe | 1 | 2011 | 46 | 0.090 |
Why?
| | Social Behavior | 1 | 2011 | 73 | 0.090 |
Why?
| | Anxiety Disorders | 1 | 2011 | 130 | 0.090 |
Why?
| | Infant, Newborn | 1 | 2018 | 2875 | 0.090 |
Why?
| | Child Behavior | 1 | 2011 | 108 | 0.080 |
Why?
| | Glycogen Storage Disease Type III | 1 | 2010 | 1 | 0.080 |
Why?
| | Glycogen Debranching Enzyme System | 1 | 2010 | 2 | 0.080 |
Why?
| | Cervical Vertebrae | 1 | 2011 | 62 | 0.080 |
Why?
| | Genetic Heterogeneity | 1 | 2010 | 20 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 528 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2011 | 196 | 0.080 |
Why?
| | Brain Mapping | 1 | 2011 | 224 | 0.080 |
Why?
| | Cleft Palate | 1 | 2011 | 79 | 0.080 |
Why?
| | Syndrome | 1 | 2010 | 252 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2010 | 252 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1372 | 0.070 |
Why?
| | Skin | 1 | 2010 | 420 | 0.070 |
Why?
| | Myocardium | 1 | 2010 | 478 | 0.070 |
Why?
| | Exercise | 1 | 2010 | 548 | 0.060 |
Why?
| | Heart Defects, Congenital | 1 | 2011 | 615 | 0.060 |
Why?
| | Obsessive-Compulsive Disorder | 1 | 2024 | 44 | 0.060 |
Why?
| | Genetic Vectors | 1 | 2024 | 130 | 0.050 |
Why?
| | Delphi Technique | 1 | 2024 | 64 | 0.050 |
Why?
| | Azo Compounds | 1 | 2022 | 11 | 0.050 |
Why?
| | Pilot Projects | 1 | 2024 | 719 | 0.050 |
Why?
| | Health Personnel | 1 | 2024 | 252 | 0.050 |
Why?
| | Electrodiagnosis | 1 | 2021 | 13 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2021 | 123 | 0.040 |
Why?
| | Pyrimidines | 1 | 2022 | 199 | 0.040 |
Why?
| | Homozygote | 1 | 2018 | 58 | 0.040 |
Why?
| | Prospective Studies | 1 | 2024 | 2449 | 0.040 |
Why?
| | Signal Transduction | 1 | 2021 | 1702 | 0.030 |
Why?
| | Flurothyl | 1 | 2013 | 1 | 0.030 |
Why?
| | Kindling, Neurologic | 1 | 2013 | 1 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2013 | 71 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2021 | 3413 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2013 | 366 | 0.020 |
Why?
| | Protons | 1 | 2012 | 71 | 0.020 |
Why?
| | Hippocampus | 1 | 2013 | 199 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 294 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 253 | 0.020 |
Why?
| | Anisotropy | 1 | 2011 | 61 | 0.020 |
Why?
| | Autoantibodies | 1 | 2011 | 121 | 0.020 |
Why?
| | Drug Resistance | 1 | 2011 | 68 | 0.020 |
Why?
| | Video Recording | 1 | 2011 | 79 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2012 | 333 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2010 | 137 | 0.020 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2011 | 133 | 0.020 |
Why?
| | Emotions | 1 | 2011 | 172 | 0.020 |
Why?
| | Exons | 1 | 2010 | 101 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 571 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 770 | 0.020 |
Why?
| | Cognition | 1 | 2011 | 330 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2013 | 1480 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 1897 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2011 | 1198 | 0.020 |
Why?
| | Mice | 1 | 2013 | 5936 | 0.010 |
Why?
| | Animals | 1 | 2013 | 13455 | 0.010 |
Why?
|
|
Veerapandiyan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|